Abigail Mitzel
Payments from drug & device makers
Across 164 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- QOL Medical, LLC$398
- Madrigal Pharmaceuticals$298
- E.r. Squibb & Sons, L.L.C.$228
- Johnson & Johnson$187
- Aimmune Therapeutics, Inc.$172
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,034 |
| QOL Medical, LLC | 19 | $398 |
| Madrigal Pharmaceuticals | 9 | $298 |
| E.r. Squibb & Sons, L.L.C. | 7 | $228 |
| Johnson & Johnson | 11 | $187 |
| Aimmune Therapeutics, Inc. | 9 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $163 |
| Sanofi | 7 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $138 |
| Lilly USA, LLC | 5 | $112 |
| Gilead | 3 | $88 |
| Phathom Pharmaceuticals, Inc. | 6 | $55 |
| Ironwood Pharmaceuticals, Inc | 3 | $47 |
| Intercept Pharmaceuticals, Inc. | 2 | $41 |
| Novo Nordisk | 1 | $40 |
| Bristol Myers Squibb | 2 | $38 |
| Braintree Laboratories, Inc. | 2 | $28 |
| Celltrion USA Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Organon | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Biocon Biologics Inc | 1 | $15 |
How this compares
$3,331 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 43 | $7,069 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 182 | $3,083 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 66 | $1,122 |
| Omeprazole | 77 | $584 |
| Pantoprazole Sodium | 23 | $335 |
| Dicyclomine Hcl | 22 | $278 |
| Sucralfate | 14 | $258 |
| Esomeprazole Magnesium | 11 | $222 |
| Famotidine | 25 | $151 |
Paid to pharmacies, not to this prescriber.
Other family in Reno
- Lisa Hammargren-KuykendallReno$22K
- Martha AiyukReno$15K
- Jocelyn AllenReno$12K
- Kaylie HumphreysReno$11K
- Christina KrainbrinkReno$10K
- Barbara SzatkowskiReno$10K
- Johanna LeeReno$9K
- Darin OldeReno$9K
- Ruth SkinnerReno$8K
- Anna EllisReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.